The role of the EQ-5D in the economic evaluation of dermatological conditions and therapies

Dermatology

Volumn 225, Issue 1, 2012, Pages 45-53

  Pereira, F R A ^a   Basra, M K A ^a   Finlay, A Y ^a   Salek, M S ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Cost effectiveness analysis; Cost of illness analysis; Cost utility analysis; Economic evaluation; EQ 5D; Health related quality of life; QALY; Skin diseases

Indexed keywords

ADALIMUMAB; ALITRETINOIN; ALPHA INTERFERON; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; EFALIZUMAB; EMOLLIENT AGENT; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PLACEBO; PSORALEN; TACROLIMUS; VARICELLA ZOSTER VACCINE;

ACNE VULGARIS; ATOPIC DERMATITIS; CHRONIC DISEASE; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DERMATOLOGY; ECONOMIC EVALUATION; EUROQOL 5D QUESTIONNAIRE; HAND ECZEMA; HEALTH CARE COST; HEALTH SERVICE; HERPES ZOSTER; HIDDEN MARKOV MODEL; HOME CARE; HUMAN; MELANOMA; MORBIDITY; MORTALITY; OUTPATIENT; OUTPATIENT CARE; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; QUALITY ADJUSTED LIFE YEAR; QUESTIONNAIRE; REVIEW; SKIN DISEASE; SYSTEMATIC REVIEW; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION;

COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HEALTH STATUS; HUMANS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; SKIN DISEASES;

EID: 84867744837     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000339865     Document Type: Review

References (34)

1. Basra MKA, Shahrukh M: Burden of skin diseases. Expert Rev Pharmacoeconomics Outcomes Res 2009; 9: 271-283.
2. Schofield J, Grindlay D, Williams H: Skin Conditions in the UK: A Health Care Needs Assessment, ed 1. Nottingham, Centre of Evidence Based Dermatology, University of Nottingham, 2009.
3. McCombs K, Chen S: Patient preference quality of life measures in dermatology. Dermatol Ther 2007; 20: 102-109. (Pubitemid 46817425)
4. Finlay AY: Quality of life measurement in dermatology: A practical guide. Br J Dermatol 1997; 136: 305-314. (Pubitemid 27105848)
5. Finlay AY: Quality of life assessments in dermatology. Semin Cutan Med Surg 1998; 17: 291-296. (Pubitemid 28555135)
6. Wyke A, Barby A, Buckley B, et al: What is 'quality of life' for patients? Br J Healthcare Manag 2008; 14: 1-8.
7. EQ-5D-3L user guide: Basic information on how to use the EQ-5D-3L instrument. 2011. Version 4.0.
8. Ellis C, Reiter K, Wheeler J, Fendrick A: Economic analysis in dermatology. J Am Acad Dermatol 2002; 46: 271-283. (Pubitemid 34118387)
9. Zuberbier T, Orlow S, Paller A, et al: Patient perspectives on the management of atopic dermatitis. J Allergy Clin Immunol 2006; 118: 226-232. (Pubitemid 43946465)
10. Balkrishnan R, Kulkarni A, Cayce K, Feldman S: Predictors of healthcare outcomes and costs related to medication use in patients with acne in the United States. Cutis 2006; 77: 251-255. (Pubitemid 43723545)
11. Scott F, Johnson R, Leedham-Green M, et al: The burden of herpes zoster: A prospective population based study. Vaccine 2006; 24: 1308-1314. (Pubitemid 43222038)
12. Aunhachoke K, Bussaratid V, Chirachanakul P, et al: Measuring herpes zoster, zoster-associated pain, post-herpetic neuralgia-associated loss of quality of life and healthcare utilization and costs in Thailand. Int J Dermatol 2011; 50: 428-435.
13. Kulkarni A, Balkrishnan R, Richmond D, et al: Medication-related factors affecting health care outcomes and costs for patients with psoriasis in the United States. J Am Acad Dermatol 2005; 52: 27-31. (Pubitemid 40038932)
14. Ghatnekar O, Ljungberg A, Lundqvist T, et al: Cost of illness of psoriasis - a 1-month prospective study in Southern Sweden. 13th Euro Abstracts, 2010, p 398.
15. Bergstrom K, Arambula K, Kimball A: Medication formulation affects quality of life: A randomized single-blind study of clobetasol propionate foam 0.05% compared with a combined program of clobetasol cream 0.05% and solution 0.05% for the treatment of psoriasis. Cutis 2003; 72: 407-411. (Pubitemid 37550149)
16. Koek M, Sigurdsson V, Weelden H, et al: Cost-effectiveness of home ultraviolet B phototherapy for psoriasis: Economic evaluation of a randomized controlled trial (PLUTO study). BMJ 2010; 340: 1-11.
17. Blank P, Blank A, Szucs T: Cost-effectiveness of oral alitretinoin in patients with severe chronic hand eczema: A long-term analysis from a Swiss perspective. BMC Dermatol 2010; 10: 4.
18. Rodgers M, Griffin S, Paulden M, et al: Alitretinoin for severe chronic hand eczema. Pharmacoeconomics 2010; 28: 351-362.
19. Dixon S, Walters SJ, Turner L, Hancock BW: Quality of life and cost-effectiveness of interferon-alpha in malignant melanoma: Results from randomised trial. Br J Cancer 2006; 94: 492-498. (Pubitemid 43289752)
20. Poole CD, Chambers C, Sidhu MK, Currie CJ: Health-related utility among adults with atopic dermatitis treated with 0.1% tacrolimus ointment as maintenance therapy over the long term: Findings from the Protopic -CONTROL study. Br J Dermatol 2009; 161: 1335-1340.
21. Poole CD, Chambers C, Allsopp R, Currie CJ: Quality of life and health-related utility analysis of adults with moderate and severe atopic dermatitis treated with tacrolimus ointment vs topical corticosteroids. J Eur Acad Dermatol Venereol 2010; 24: 674-678.
22. Sizto S, Bansback N, Feldman SR, Willian MK, Anis AH: Economic evaluation of systemic therapies for moderate to severe psoriasis. Br J Dermatol 2009; 160: 1264-1272.
23. Parsi K, Chambers CJ, Armstrong AW: Costeffectiveness analysis of a patient-centered care model for management of psoriasis. J Am Acad Dermatol 2012; 66: 563-570.
24. Weiss S, Rehmus W, Kimball A: An assessment of the cost-utility of therapy for psoriasis. Ther Clin Risk Manag 2006; 2: 325-328. (Pubitemid 44349508)
25. Rothberg M, Virapongse A, Smith K: Costeffectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis 2007; 44: 1280-1288. (Pubitemid 46717289)
26. Hornberger J, Robertus K: Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med 2006; 145: 317-325. (Pubitemid 46768588)
27. Pellissier JM, Brisson M, Levin MJ: Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine 2007; 25: 8326-8337. (Pubitemid 350087379)
28. Hoek AJ, Gay N, Melegaro A, Opstelten W, Edmunds WJ: Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine 2009; 27: 1454- 1467.
29. Woolacott N, Hawkins N, Mason A, Kainth A, Khadjesari Z, Vergel YB, Misso K, Light K, Chalmers R, Sculpher M, et al: Etanercept and efalizumab for the treatment of psoriasis: A systematic review. Health Technol Assess (Winchester) 2006; 10: 1-233, i-iv.
30. Gray AM, Rivero-Arias O, Clarke PM: Estimating the association between SF-12 responses and EQ5D utility values by response mapping. Med Decis Making 2006; 26: 18.
31. Coplan PM, Schmader K, Nikas A, et al: Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: Adaptation of the brief pain inventory. J Pain 2004; 5: 344-356. (Pubitemid 39164674)
32. Kind P, Dolan P, Gudex C, Williams A: Variations in population health status: Results from a United Kingdom national questionnaire survey. BMJ 1998; 316: 736-741. (Pubitemid 28121072)
33. Chen SC, Bayoumi AM, Soon SL, et al: A catalog of dermatology utilities: A measure of the burden of skin diseases. J Investig Dermatol Symp Proc 2004; 9: 160-168. (Pubitemid 38457275)
34. Norlin JM, Carlsson KS, Persson U, Schmitt-Egenolf M: Analysis of three outcome measures in moderate to severe psoriasis: A registry-based study of 2,450 patients. Br J Dermatol 2012; 166: 797-802.